Pamela Madsen, Founder of American Fertility Association Joins One of the Nation's Largest Infertility Care Networks
LAS VEGAS, Nev. -- The Sher Institutes for Reproductive Medicine(R) announced today that Pamela Madsen has been named as Director of Client/Practice Relations to...
Intravenous Infusions of Epeius Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue...
Detroit Dads Opt for Cosmetic Enhancement, Not Power Tools, This June
STERLING HEIGHTS, Mich. -- "Age is a question of mind over matter. If you don't mind, it doesn't matter," said Satchel Paige... but, if...
Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
SAN MARINO, Calif. -- ASCO 2008 -- Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene...
M2SYS Fingerprint Software Integrated with Medical Marijuana Dispensary Solution
ATLANTA, Ga. -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has finalized an agreement with IMCL (Innovative...
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...
Affinity Healthcare Receives Accreditation for CT and Ultrasound
ARLINGTON HEIGHTS, Ill. -- Affinity Healthcare LLC's diagnostic imaging practice located at 1051 W. Rand Road, Arlington Heights, IL was recently awarded accreditation for...
PreViser and Oral Health Innovations Ltd Form UK Partnership
MOUNT VERNON, Wash. -- PreViser Corporation (www.previser.com), a Washington State-based provider of patented oral disease and risk assessment technology to the dental profession, announced...
Illinois Based Affinity Healthcare, LLC Adds New Physicians
ARLINGTON HEIGHTS, Ill. -- Affinity Healthcare, LLC is pleased to announce the recent addition of two new physicians to its Internal Medicine clinical staff....
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G.
